Readers may encounter GLP-3 as a catalog or search term. The clinical literature names the investigational molecule retatrutide or LY3437943 and identifies its targets as GLP-1, GIP and glucagon receptors.
Receptor names versus catalog terms
A product label and a clinical study intervention are distinct sources of information. A shared search term does not establish identity, quality or equivalence with the material used in a trial.
How to interpret the evidence
For evidence searches, start with retatrutide or LY3437943 and verify the exact intervention in the study methods.
Start with the intervention name and receptor targets, then follow the links to the original trial if you want to check what was measured in people.